Kala Bio (KALA) Preferred Stock Liabilities (2016 - 2017)

Kala Bio (KALA) posted Preferred Stock Liabilities of $10.7 million for Q3 2017, down 51.61% sequentially from $22.2 million in Q2 2017.

Kala Bio (KALA) Preferred Stock Liabilities (2016 - 2017) Analysis & Trends

Kala Bio has reported Preferred Stock Liabilities for 2 years, with the latest figure at $10.7 million in Q3 2017.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $10.7 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $10.7 million (changed N/A YoY) and the FY2016 annual result came in at $67.5 million, up 510.21% from the prior year.
Preferred Stock Liabilities retreated to $10.7 million in Q3 2017 per KALA's latest filing, from $22.2 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $67.5 million in Q4 2016 and troughed at $10.7 million in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Kala Bio	9.89 Mn	9.89 Mn	-	-

Download Data